The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with BRCA1/2-associated breast cancer have good survival outcomes and are living longer, but this raises the ...

Do you have any thoughts about the effect of oral contraceptives on tubo-ovarian cancer risk in BRCA1/2 mutation carriers? Based on the observed age of onset of these tubo-ovarian cancers ...

have conducted the largest study done to date of BRCA1 and BRCA2 (BReast CAncer Gene 1 and 2) carriers in an Asian population and refined breast and ovarian cancer risk estimates for this population.

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

It is recommended that prophylactic surgery should be performed as soon as possible, simply because of the early development of cancer in BRCA mutation carriers. Although ovarian cancer rarely ...

Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

By comparison, the average U.S. woman has a 13.2 percent chance of developing breast cancer. Why do these BRCA mutations increase cancer risk? All cancers are characterized by uncontrolled cell ...

MIAMI – Beyoncé’s mother and father have both survived breast cancer. While promoting her new memoir “Matriarch,” her mother, ...